Publication NumberUS 4607009
Assignees
  • The Wistar Institute
StatusIssued Patent
Application Number06/532891
AvailabilityUnknown
Filing Date1983-09-16
Publication Date1986-08-19

Abstract

An assay for determining the Lewis blood group of a patient consists of testing a body sample for the presence of Lewis.sup.a and Lewis.sup.b antigens. Monoclonal antibodies specific for either of these antigens are employed which do not cross-react with other related antigens, such as the H blood antigen. Body samples which may be tested include: saliva, serum, urine, and paraffin-embedded tissue samples. Hybridoma cell lines and the antibody compositions they produce specific for these antigens are provided for use in the assay.

Claims

  • 1. A method of determining Lewis blood group comprising contacting a test sample selected from the group consisting of human tissue and human body fluid, with monoclonal antibodies, under conditions which permit the formation of antigen-antibody complexes and determining the presence or absence of said antigen-antibody complexes, said monoclonal antibodies binding to the same antigenic determinants as monoclonal antibodies produced by (a) fused cell hybrid ATCC HB 8324 and (b) a fused cell hybrid selected from the group consisting of ATCC HB 8325 and ATCC HB 8326.
  • 2. The method of claim 1 wherein said test sample is selected from the group consisting of saliva and serum.
  • 3. The method of claim 1 wherein said test sample is saliva.
  • 4. The method of claim 1 further comprising determining the presence or absence of said antigen-antibody complexes wherein said monoclonal antibodies binding to the same antigenic determinants as monoclonal antibodies selected from the group consisting of monoclonal antibodies produced by fused cell hybrid ATCC HB 8322 and ATCC HB 8323.
  • 5. The method of claim 2 further comprising determining the presence or absence of said antigen-antibody complexes wherein said monoclonal antibodies binding to the same antigenic determinants as monoclonal antibodies selected from the group consisting of monoclonal antibodies produced by fused cell hybrid ATCC HB 8322 and ATCC HB 8323.
  • 6. The method of claim 3 further comprising determining the presence or absence of said antigen-antibody complexes wherein said monoclonal antibodies binding to the same antigenic determinants as monoclonal antibodies selected from the group consisting of monoclonal antibodies produced by fused cell hybrid ATCC HB 8322 and ATCC HB 8323.
  • 7. A method of determining Lewis blood group phenotype comprising contacting a sample selected from the group consisting of human saliva and human blood with monoclonal antibodies under conditions which permit the formation of antigen-antibody complexes and determining the presence or absence of said antigen-antibody complexes, wherein said monoclonal antibodies are produced by fused cell hybrid ATCC HB 8324 and a fused cell hybrid selected from the group consisting of ATCC HB 8325 and ATCC HB 8326.
  • 8. The method of claim 7 wherein the means by which the presence or absence of said antigen-antibody complexes is determined is a radioimmunoassay.
  • 9. The method of claim 7 wherein the means by which the presence or absence of said antigen-antibody complexes is determined is an enzyme-linked immunoabsorbent assay.
  • 10. A method of determining Lewis blood group phenotype comprising: (a) providing at least two solid support members contacted with a human saliva sample, said solid support members having the ability to immobilize glycolipids or glycoproteins; (b) contacting a first said solid support member with monoclonal test antibodies binding to the same antigenic determinants as monoclonal antibodies produced by fused cell hybrid ATCC HB 8324, under conditions which permit the formation of antigen-antibody complexes; (c) contacting a second said solid support member with monoclonal test antibodies binding to the same antigenic determinants as monoclonal antibodies produced by a fused cell hybrid selected from the group consisting of ATCC HB 8325 and ATCC HB 3826, under conditions which permit the formation of antigen-antibody complexes; (d) after said monoclonal test antibody-contacting steps, contacting each of said solid support members with indicator antibodies that selectively bind said monoclonal test antibodies under conditions which permit the formation of antigen-antibody-antibody complexes; and (e) determining the presence or absence of said antigen-antibody-antibody complexes on said solid support member.
  • 11. The method of claim 10 wherein said step (e) comprises a method selected from the group consisting of a radioimmunoassay and an enzyme-linked assay.
  • 12. The method of claim 10 wherein a third saliva-contacted solid support member is contacted with a monoclonal test antibody binding to the same antigenic determinants as antibodies produced by a fused cell hybrid selected from the group consisting of fused cell hybrids ATCC HB 8322 and ATCC HB 8323 under conditions which permit the formation of antigen-antibody complexes.
  • 13. The fused cell hybrid ATCC HB 8322.
  • 14. The fused cell hybrid ATCC HB 8323.
  • 15. The fused cell hybrid ATCC HB 8324.
  • 16. The fused cell hybrid ATCC HB 8325.
  • 17. The fused cell hybrid ATCC HB 8326.
  • 18. Monoclonal antibodies produced by the fused cell hybrid ATCC HB 8322.
  • 19. Monoclonal antibodies produced by the fused cell hybrid ATCC HB 8323.
  • 20. Monoclonal antibodies produced by the fused cell hybrid ATCC HB 8324.
  • 21. Monoclonal antibodies produced by the fused cell hybrid ATCC HB 8325.
  • 22. Monoclonal antibodies produced by the fused cell hybrid ATCC HB 8326.

Related Grants

31 related grants.

Sign in to view

Related Publications

100 related publications.

Sign in to view

Covalent Data is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.

Create a Free account today to see all results.
Get all Pro account features for 14 days.

Join today for free

No credit card required